Journal of Bone Research
Open Access

Abstract

Osteoblastic Differentiation's Inhibition Mediated by Nicotinamide

Fernando Rivas-Valdés, Iván L. Quevedo, Soraya Gutiérrez, Gustav A. Von Plessing-Pierry

Heterotopic Ossification is a pathological process that is defined as extraskeletal bone formation in both muscle and soft
tissue. The most severe condition of HO, a rare genetic form, is the Fibrodysplasia Ossificans Progressive (FOP). Some data
suggest that nicotinamide therapy shows major clinical improvement in patients with FOP. This relational analytic study
seeks to present the results of molecular findings of the effect of nicotinamide in the differentiation of C2C12 cell line
to osteoblasts. To assess this objective, cells were cultured, immunochemistry histologic, and molecular assays were run to
analyze the effect of nicotinamide in osteoblastic differentiation in different times of exposure to BMP2 and/or nicotinamide.
Nicotinamide inhibits osteoblastogenesis in a dose-dependent way in vitro in the C2C12 cell line. It has an inhibitory effect on
the phosphorylation of the Smad 1/5/8 complex without a significant difference in osteoblastogenesis classic gene expression.
The rational use of nicotinamide could be of great clinical utility as a new preventive therapeutic tool in pathologies where
bone formation occurs in extra-skeletal sites.

Published Date: 2020-09-24; Received Date: 2020-07-17